- Stocks
- Pharma & Healthcare
- Fortis Healthcare
Fortis Healthcare share price
NSE: FORTISPharma & HealthcareMedical Care Facilities
Fortis Healthcare at a glance
Fortis Healthcare (NSE: FORTIS) closed at ₹720.15 on 22 Oct 2026, down 0.67% on the day. With a market capitalisation of ₹54,859 Cr, it ranks 184th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 52.3× trailing earnings, against a return on equity of 10.5% in FY26. Over the past year the share price has fallen 33.5%. Its 52-week range is ₹710.80 (22 Oct 2026) to ₹1,104.00 (23 Oct 2025); the last close is 34.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,545 Cr (+17.5% year on year) and net profit ₹268 Cr (+1.7%), on a consolidated basis. Promoters held 31.17% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹54,859 CrRank 184 on NSE
- P/E (trailing)
- 52.3×
- Price to book
- 6.06×FY26
- EPS (TTM)
- ₹13.88to Q1 FY27
- ROE
- 10.5%FY26
- ROCE
- 12.2%FY26
- Debt to equity
- 0.29FY26
- Net profit margin
- 11.5%FY26
- Book value / share
- ₹131.07FY26
- 52-week high
- ₹1,104.0023 Oct 2025
- 52-week low
- ₹710.8022 Oct 2026
- 1-year return
- −33.5%
- RSI (14-day)
- 22.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.67% | −3.3% | −19.6% | −24.2% | −33.5% |
Fortis Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,988 Cr | ₹1,928 Cr | ₹2,007 Cr | ₹2,167 Cr | ₹2,331 Cr | ₹2,265 Cr | ₹2,365 Cr | ₹2,545 Cr |
| Revenue YoY | +12.3% | +14.8% | +12.4% | +16.6% | +17.3% | +17.5% | +17.8% | +17.5% |
| Net profit | ₹189 Cr | ₹252 Cr | ₹183 Cr | ₹264 Cr | ₹325 Cr | ₹194 Cr | ₹265 Cr | ₹268 Cr |
| Net profit YoY | +3.4% | +94.5% | −7.8% | +52.2% | +72.2% | −23.1% | +44.5% | +1.7% |
| Net margin | 9.5% | 13.1% | 9.1% | 12.2% | 13.9% | 8.6% | 11.2% | 10.5% |
| EPS | ₹2.34 | ₹3.28 | ₹2.44 | ₹3.45 | ₹4.26 | ₹2.57 | ₹3.52 | ₹3.53 |
Fortis Healthcare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹4,030 Cr | ₹5,718 Cr | ₹6,298 Cr | ₹6,893 Cr | ₹7,783 Cr | — |
| Operating profit | −₹5 Cr | ₹649 Cr | ₹718 Cr | ₹832 Cr | ₹1,085 Cr | — |
| Net profit | −₹104 Cr | ₹766 Cr | ₹611 Cr | ₹636 Cr | ₹798 Cr | — |
| EPS (₹) | −₹1.00 | ₹7.00 | ₹8.00 | ₹8.00 | ₹10.00 | — |
| Cash from operations | ₹485 Cr | ₹865 Cr | ₹822 Cr | ₹1,100 Cr | ₹1,424 Cr | — |
| Total debt | ₹968 Cr | ₹779 Cr | ₹572 Cr | ₹741 Cr | ₹2,086 Cr | ₹2,401 Cr |
| Shareholders' equity | ₹6,120 Cr | ₹6,178 Cr | ₹7,242 Cr | ₹7,663 Cr | ₹8,917 Cr | ₹9,896 Cr |
Fortis Healthcare shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% | 31.17% |
| Foreign institutions | 27.40% | 27.17% | 27.90% | 27.84% | 25.97% | 25.20% |
| Domestic institutions | 29.46% | 29.79% | 29.14% | 29.33% | 31.35% | 32.23% |
| Non-institutions | 11.97% | 11.87% | 11.79% | 11.67% | 11.51% | 11.40% |
Fortis Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Fortis Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALKEMAlkem Laboratories | ₹4,972.00 | −0.58% | −9.6% | ₹59,962 Cr | 25.8 | 16.6% |
| ASTERDMAster DM Health | ₹647.20 | −0.46% | −5.5% | ₹56,672 Cr | 101.1 | 8.5% |
| FORTISFortis Healthcare | ₹720.15 | −0.67% | −33.5% | ₹54,859 Cr | 52.3 | 10.5% |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹53,888 Cr | 34.8 | 33.4% |
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹53,829 Cr | 117.6 | 1.1% |
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹48,683 Cr | 43 | 14.2% |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹47,020 Cr | 46.7 | 9.9% |
Ask anything about Fortis Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against FORTIS's own history. Try: “Why has FORTIS moved over the last three months?” · “Backtest a 50-day moving-average crossover on FORTIS over five years” · “Compare FORTIS with ALKEM on margins and valuation”
Frequently asked questions about Fortis Healthcare
What is the share price of Fortis Healthcare today?
Fortis Healthcare (NSE: FORTIS) last closed at ₹720.15 on 22 Oct 2026. Its 52-week high is ₹1,104.00 and its 52-week low is ₹710.80.
What is the market cap of Fortis Healthcare?
Fortis Healthcare's market capitalisation is ₹54,859 Cr (₹54,859 Cr) at the 22 Oct 2026 close, ranking 184th among the NSE companies Pivot tracks.
What is the P/E ratio of Fortis Healthcare?
Fortis Healthcare trades at a trailing P/E of 52.3. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of Fortis Healthcare?
Return on equity was 10.5% in FY26 and return on capital employed was 12.2% in FY26 (consolidated figures).
Is Fortis Healthcare a debt-free company?
No. Fortis Healthcare's debt-to-equity ratio was 0.29 in FY26, with total debt of ₹2,401 Cr.
What were Fortis Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Fortis Healthcare reported revenue of ₹2,545 Cr, +17.5% year on year, and net profit of ₹268 Cr, +1.7% year on year.
How has Fortis Healthcare stock performed over the last year?
Fortis Healthcare's share price has fallen 33.5% over the past year, −24.2% over three months and −19.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Fortis Healthcare?
As of 30 Jun 2026: promoters 31.17%, foreign institutions 25.20%, domestic institutions 32.23%, non-institutions 11.40%.
Who are Fortis Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Fortis Healthcare by market cap are Alkem Laboratories, Aster DM Health, Abbott India, Biocon, IPCA Laboratories and Gland Pharma.
Is Fortis Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Fortis Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FORTIS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text